{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T06:56:06Z","timestamp":1781938566240,"version":"3.54.5"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:00:00Z","timestamp":1774051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:00:00Z","timestamp":1774051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40265-026-02298-x","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T04:11:50Z","timestamp":1774066310000},"page":"765-768","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Sibeprenlimab: First Approval"],"prefix":"10.1007","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6519-7831","authenticated-orcid":false,"given":"Arnold","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,21]]},"reference":[{"issue":"5","key":"2298_CR1","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1080\/14712598.2024.2346111","volume":"24","author":"SA Doggrell","year":"2024","unstructured":"Doggrell SA. Sibeprenlimab, which neutralizes A PRoliferation Inducing Ligand (APRIL), as a new approach to treating IgA nephropathy. Expert Opin Biol Ther. 2024;24(5):335\u20138.","journal-title":"Expert Opin Biol Ther"},{"key":"2298_CR2","unstructured":"US Food & Drug Administration. FDA approves a new treatment for primary immunoglobulin A nephropathy [media release]. 25 Nov 2025. https:\/\/www.fda.gov\/."},{"key":"2298_CR3","unstructured":"CTIS. Trial of sibeprenlimab in the treatment of Sj\u00f6gren\u2019s disease. https:\/\/trialsearch.who.int\/Trial2aspx?TrialID=CTIS2024-516295-14-00. 2024."},{"key":"2298_CR4","unstructured":"Otsuka Pharmaceutical. VOYXACT\u00ae (sibeprenlimab-szsi) injection: US prescribing information. 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761434s000lbl.pdf. Accessed 14 Jan 2025."},{"key":"2298_CR5","unstructured":"Visterra. Otsuka Pharmaceutical completes acquisition of Visterra [media release]. 4 Sep 2018. http:\/\/www.visterrainc.com."},{"key":"2298_CR6","unstructured":"Myette JR, Shriver ZH, Viswanathan K, inventors, et al. Antibody molecules to a proliferation-inducing ligand (APRIL) patent US10385123B2. 2018."},{"issue":"12","key":"2298_CR7","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1002\/cpdd.1316","volume":"12","author":"X Zhang","year":"2023","unstructured":"Zhang X, Wang Y, Yarbrough J, et al. Safety, pharmacokinetics, and pharmacodynamics of subcutaneous sibeprenlimab in healthy participants. Clin Pharmacol Drug Dev. 2023;12(12):1211\u201320.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2298_CR8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2512133","author":"V Perkovic","year":"2025","unstructured":"Perkovic V, Trimarchi H, Tesar V, et al. Sibeprenlimab in IgA nephropathy\u2014interim analysis of a phase 3 trial. N Engl J Med. 2025. https:\/\/doi.org\/10.1056\/NEJMoa2512133.","journal-title":"N Engl J Med"},{"issue":"1","key":"2298_CR9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa2305635","volume":"390","author":"M Mathur","year":"2024","unstructured":"Mathur M, Barratt J, Chacko B, et al. A phase 2 trial of sibeprenlimab in patients with IgA nephropathy. N Engl J Med. 2024;390(1):20\u201331.","journal-title":"N Engl J Med"},{"issue":"5","key":"2298_CR10","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.ekir.2022.01.1073","volume":"7","author":"M Mathur","year":"2022","unstructured":"Mathur M, Barratt J, Suzuki Y, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of VIS649 (sibeprenlimab), an APRIL-neutralizing IgG(2) monoclonal antibody, in healthy volunteers. Kidney Int Rep. 2022;7(5):993\u20131003.","journal-title":"Kidney Int Rep"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02298-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02298-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02298-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T03:48:49Z","timestamp":1777002529000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02298-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,21]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2298"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02298-x","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,21]]},"assertion":[{"value":"15 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Arnold Lee is a contracted employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}